Axoltis Pharma is a clinical-stage biopharmaceutical company developing NX210c, an innovative treatment for amyotrophic lateral sclerosis (ALS)—a disease with a significant unmet medical need. NX210c works by restoring the blood-brain barrier, a key mechanism also implicated in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.

Last year, investors in the previous round received warrants (BSAs) equivalent to their initial investment—the right to reinvest once the results of the Phase 2 clinical trial were known. That moment has arrived: the results were presented on June 24, 2026, at the ENCALS congress in Madrid.

The exercise of warrants is organized in three phases. In the first phase, which begins on July 3 and lasts 10 days, each investor can exercise their warrants up to 100% of their initial investment. If, at the end of this phase, less than 85% of the total allocation has been covered, a second phase of 7 to 10 days opens, in which investors can reinvest up to the initial amount. Any warrants remaining unexercised after these two phases will be allocated in a third round on a first-come, first-served basis. The deadline for transferring the funds is August 10, 2026.

The technical terms are as follows: 2 warrants are equivalent to 1 new ordinary share, at an exercise price of €20.80 per share. The total reserve of the investment vehicle (STAK) is 211,434 warrants, which allows the acquisition of up to 105,717 new shares, for a total amount of €2,198,913.60.

This warrant allocation is part of a broader €8.1M financing round open to all Axoltis shareholders.

Completed 17 a day ago
656 investors
Investment achieved
2.198.920€
Target
1.500.000€
Invested
146.6%
146.6% INVESTED
This campaign was live:
From: 30 September 2025
Until: 17 November 2025
Maturity

Premarket/clinical phase

Premoney valuation

14.409.782€

Estimated exit

H2 2026

Sector

New drugs

Equity offered

41.22%

Minimum investment

1.000€

Lyon flag
Equity L
Tax deduction
close modal
Share this opportunity

Share on your social channels

Select the social platform

Share this project on your website.

Copy and paste the following code into your content.

Overview: AXOLTIS Pharma

Valuation 14.409.782€
Estimated return x20
% Offered 41.22%
Estimated exit H2 2026

An indication for a wide range of neurological diseases with disruption of the blood-brain barrier, including ALS, Alzheimer's, Parkinson's, and multiple sclerosis.

A drug candidate in phase II clinical trials, demonstrating an excellent safety and tolerability profile since its first human trials in 2020.

Orphan drug designation granted by the FDA and EMA.

Preclinical studies have shown promising results in several in vitro and in vivo models of neurodegenerative and neurotraumatic diseases.

Nominated for the Prix Galien USA 2024 —the equivalent of the Nobel Prize in health— in the Best Startup category.

The potential market for ALS drug candidates is over one billion dollars

The global market for neurodegenerative diseases is expected to nearly double in the next decade, going from about $52 billion in 2024 to around $102.4 billion in 2034.

Potential for a 20x exit in less than a year, by mid-2026, based on the results of our ongoing phase 2 clinical trial in ALS patients.

Axoltis Pharma is a pioneer in an innovative treatment for ALS and multiple neurodegenerative disorders.

Axoltis Pharma is developing NX210c, a first-in-class therapeutic candidate targeting amyotrophic lateral sclerosis (ALS) and a broad range of central nervous system (CNS) diseases. At the heart of our innovation is a unique peptide with extraordinary properties, notably the ability to repair the blood-brain barrier (BBB) . Disruption of this protective blood-brain barrier is now recognized as a key trigger and amplifier of several major neurodegenerative diseases, including Alzheimer’s, Parkinson’s, multiple sclerosis, and ALS. Given the strong scientific and medical rationale, and the fact that ALS is a significant unmet medical need affecting 500,000 patients worldwide without an effective treatment, it was selected as the first therapeutic indication for NX210c.

The disruption of the blood-brain barrier: a trigger and an accelerator of neurodegeneration

New evidence points to blood-brain barrier (BBB) dysfunction as a key factor in neurodegenerative diseases. The BBB acts as a crucial intermediary between the bloodstream and the brain, regulating the passage of nutrients and molecules. When it is compromised, harmful proteins infiltrate the brain, causing inflammation and neuronal damage. Diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, ALS, and many others share this underlying mechanism. Therefore, repairing the integrity of the BBB is a very promising avenue in the therapeutic arsenal for halting disease progression.

NX210c: a peptide with key properties

NX210c is a short synthetic peptide inspired by SCO-espondin, a multifunctional glycoprotein essential for neurogenesis, the process by which new neurons are formed in the brain . This peptide not only restores the blood-brain barrier (BBB) but also protects neurons and promotes intercellular communication. Its impact could be transformative, potentially slowing, halting, or even reversing neurological damage.

Focusing first on ALS: an urgent and unmet need

ALS is a rapidly progressing, fatal neuromuscular disease characterized by the death of motor neurons responsible for walking, speech, swallowing, and breathing. It affects more than 500,000 people worldwide, with an average survival of only 3 to 5 years after diagnosis. To date, there is no therapeutic option. By restoring the blood-brain barrier (BBB), NX210c offers a completely novel mechanism of action and new hope for patients.

A range of opportunities in the field of neurodegenerative diseases

The mechanism of action of NX210c opens up opportunities far beyond ALS. Its ability to restore the blood-brain barrier (BBB) could be relevant in a wide range of CNS conditions. The global market for neurodegenerative diseases is projected to nearly double over the next decade, growing from approximately $52 billion in 2024 to approximately $102.4 billion in 2034.

Promising preclinical and phase 1b results are driving rapid progress towards phase 2

Robust preclinical studies on blood-brain barrier restoration and in a murine model of ALS showed a delay in the decline of motor function and increased survival. In a 2023 phase 1b trial with healthy elderly volunteers, NX210c demonstrated an excellent safety and tolerability profile, with no serious adverse events. Preliminary pharmacodynamic signals confirmed its blood-brain barrier-restoring activity through biomarker analysis. (Click here to read the publication.) This paved the way for a phase 2 trial.

A top-level team ready to scale

Led by Dr. Yann Godfrin, CEO and serial biotech entrepreneur with 25 years of experience in corporate management, drug development, and innovation, Axoltis has assembled a multidisciplinary team of experts in neurology, clinical development, and regulatory affairs . The company is fully equipped to scale development quickly and efficiently.

A pioneering drug candidate with multiple patents

NX210c is an innovative disease-modifying drug, protected by seven patent families and granted orphan drug designation by the FDA and EMA. Orphan drugs benefit from market exclusivity once they receive marketing authorization for 10 years in the EU and 7 years in the US. Recently, in recognition of its innovative potential, Axoltis was nominated for the 2024 Prix Galien USA in the Best Startup category, considered the Nobel Prize of pharmaceutical innovation . Among its numerous and esteemed partners and sponsors, Axoltis is proud to have the valuable collaboration and support of ARSLA, the French Association for ALS Research.

Phase 2 in progress, first due diligence underway

A multicenter phase 2 trial in 80 ALS patients across France , coordinated by Dr. Bernard (HCL, Reference Center for ALS, Lyon, France), is currently recruiting participants. Preliminary results are expected in May 2026. Among several pharmaceutical companies interested in collaborating once the preliminary results are available, two have already initiated due diligence to explore licensing opportunities. This indicates strong market interest and an exceptional opportunity for investors, with a potential exit from X20 starting in 2026.

Axoltis’s mission

Axoltis is driven by an ambitious goal: to change the lives of millions of patients affected by neurodegenerative diseases, starting with ALS patients. With an innovative approach and a value creation strategy guided by a clear vision for drug development, we are at a pivotal turning point.

Join us now in the fight against ALS and help us bring to market a therapy with the potential to transform the future of neurological care.

In Capital Cell's own words

If you were on social media in 2014, you probably remember the Ice Bucket Challenge. What started as a viral joke raised $115 million in just one year for ALS, a rare and devastating disease that progressively paralyzes the body while leaving the mind intact. Stephen Hawking was a prime example.

After 85 years of research, the cause of ALS is still not fully understood. One of the first signs is the disruption of the blood-brain barrier (BBB), the brain’s natural defense. When it fails, harmful substances can enter and disrupt communication between neurons and immune cells. Restoring it could slow the progression of the disease.

Axoltis Pharma’s lead drug, NX210c (an orphan drug), has demonstrated in preclinical studies its ability to restore the blood-brain barrier (BBB), improve cell signaling, and protect neurons. And not just for ALS: BBB disruption also occurs in Alzheimer’s, Parkinson’s, multiple sclerosis, and brain injuries—a $52 billion market.

NX210c has already demonstrated excellent safety and initial biological activity in a Phase Ib trial, allowing it to proceed to Phase II trials in patients. It is therefore not surprising that two pharmaceutical companies—including a large Japanese firm—are currently conducting due diligence for a potential license.

Now you can join a funding round with advantageous valuation terms, alongside a French family office with extensive experience in the healthcare sector. A unique opportunity to support a promising therapy targeting the central nervous system.

Minimum investment: 1.000€
Type of exit expected: M&A
Drag-along rights
Tag-along rights
Preferential liquidation rights
Anti-dilution rights
Tax deductions
Main risks

While the project is very promising, there are certain risks to consider. First, the €8 million funding round must be completed for Capital Cell investors to join, and to date, €3 million has been raised, making the round’s success a significant milestone. Second, ALS is a highly complex disease with no clearly identified cause, meaning that, like other approaches, this treatment may not offer a definitive cure. Finally, although initial data and preclinical signals are encouraging, efficacy results are still pending and will be key to validating the active ingredient’s therapeutic potential.

Register now to see the full pitch of AXOLTIS Pharma.

NX210c, a drug candidate in phase 2 trials to combat amyotrophic lateral sclerosis (ALS) and a wide range of diseases n
Register with your email

Already have an account? Please login here .